212 results about "Tumor recurrence" patented technology

The invention discloses a tumor recurrence risk assessment and early warning system based on data analysis, and belongs to the technical field of medical information. The invention discloses a tumor recurrence risk assessment and early warning system based on data analysis. The system comprises a multi-data collection module, a big data processing platform, a model architecture system and an individual data processing system. According to the invention, the problems of lack of big data support, limited individualized prediction ability and insufficient real-time performance and continuous monitoring in the prior art are solved; according to the method, large-scale historical case data are integrated, the rich data sets are used for model training, the accuracy and generalization ability of a prediction model can be remarkably improved, multiple data sources such as genomics information, living habits and environmental factors are integrated, personalized risk assessment is provided for each patient, and the risk assessment efficiency is improved. The real-time monitoring interface is connected with various intelligent medical devices to collect the daily physiological parameter change condition of the patient, and continuous health management suggestions are provided for the tumor postoperative patient.

The invention discloses a gravitational field model-based lattice space segmentation radiotherapy lattice point optimization method, and relates to the technical field of radiotherapy. According to the method, by combining a PET-CT functional image, a key region, especially a hypoxic region (functional target region), of a tumor is recognized more accurately, and the positions and the distances of lattice points are dynamically adjusted according to biological characteristics of the tumor; arrangement of lattice points is dynamically adjusted through a gravitational field model, it can be guaranteed that a high-dose area accurately covers a key area of a tumor, unnecessary side effects can be reduced to the maximum extent, the risk of tumor recurrence is reduced, the method can better adapt to functional heterogeneity of the tumor, personalized treatment is achieved, and the method has good application prospects. And the influence on normal tissues is reduced while the treatment accuracy is improved, a more reliable treatment scheme is provided for treatment of complex tumors, and accurate dose distribution aiming at different tumor biological characteristics is realized.

The invention discloses a tumor recurrence risk prediction method and system based on electronic medical record data, and relates to the field of electronic medical record data processing and analys.The historical electronic medical record data are processed in a structured mode, a recurrence risk mapping model is established, individualized recurrence risk assessment can be achieved based on multi-dimensional features, and the tumor recurrence risk prediction accuracy is improved. The subjective judgment error is obviously reduced; a risk level layering mechanism can automatically distinguish patients needing emergency intervention and conventional monitoring, excessive medical treatment or delayed treatment is avoided, and the method is particularly suitable for chronic diseases such as tumors needing long-term management; through periodic marker measurement and risk level feedback, closed-loop management of evaluation-intervention-re-evaluation is formed, and the requirement for continuous optimization of clinical diagnosis and treatment is met; in addition, through preprocessing, the preprocessed multi-dimensional features can be directly called subsequently, and repeated data cleaning work is avoided.

The invention discloses a recurrence-resistant cell strain for colorectal cancer large segmentation radiotherapy and application, and relates to the technical field of cell biology. The colorectal cancer large segmentation radiotherapy recurrence-resistant cell strain is preserved in the China Center for Type Culture Collection on January 2, 2025, the preservation address is Wuhan University, Wuhan, China, and the preservation number is CCTCC NO: C202533. By constructing the colorectal cancer large segmentation radiotherapy recurrence-resistant cell strain, a new biological material is provided for studying the radiotherapy recurrence-resistant colorectal cancer. The cell strain is screened in a mouse body with a sound immune system, has better physiological correlation, and is beneficial to research on the influence of an immune microenvironment on tumor cell radiotherapy resistance and the remodeling effect of radiotherapy resistant cells on the immune microenvironment. The cell strain can also monitor tumor recurrence after radiotherapy in real time through fluorescence imaging.

The invention discloses a zinc-selenium doped white calcium stone injectable hydrogel for treating melanoma and a preparation method of the zinc-selenium doped white calcium stone injectable hydrogel. The preparation method comprises the following steps: 1, preparing hydrophilic zinc-selenium doped white calcium stone; 2, preparing oxidized sodium alginate; and (3) dispersing the hydrophilic zinc-selenium-doped white phosphorus calcium stone into the oxidized sodium alginate solution, adding the carboxymethyl chitosan solution, and uniformly mixing to obtain the zinc-selenium-doped white phosphorus calcium stone injectable hydrogel for treating melanoma. The injectable hydrogel prepared by the invention has good injectability, self-healing property and biocompatibility, and is suitable for tumor wound models with any shape and depth; the composition has good effects of promoting normal cell proliferation and inhibiting tumor cell growth, and can be used for tumor postoperative treatment to inhibit tumor recurrence and promote surgical defective tissue repair.

A computer implemented method of distinguishing tumor progression from treatment-related necrosis in digital images of a subject implements a multimodal deep learning architecture from MRI data of a selected anatomical portion of the subject, such as a brain, and corresponding dPET data for the subject with a tracer applied to the anatomical portion of the subject. The computer stores co-registered MRI data frames with dPET data frames as three dimensional (3D) parametric PET maps to identify multi-modal image features of segmented tumor data. A convolutional neural network uses MRI data and selected multi-modal image features as inputs and the computer concatenates respective output latent feature vectors from the respective sections of the at least one CNN. Feeding concatenated feature vectors to fully connected layers of the multimodal architecture distinguishes tumor progression from treatment-related necrosis of the anatomical portion of the subject.

The invention relates to a multiple myeloma model with extramedullary lesion as well as a construction method and application thereof. The multiple myeloma model is obtained by injecting bone marrow mononuclear cells (BMMC) of a multiple myeloma patient into an hIL-6NSG mouse. The invention provides a new model of multiple myeloma with extramedullary lesion, which not only is beneficial to research on gene pathway and mechanism of the multiple myeloma, but also lays a foundation for research on tumor recurrence, preclinical drug screening, effect evaluation and the like, and has great significance in promoting disease healing.

The invention discloses preparation and application of an ROS (reactive oxygen species) / temperature dual-response hydrogel vaccine capable of simultaneously delivering mRNA (messenger ribonucleic acid) and siSiglecE. The vaccine is prepared by preparing an ROS / temperature dual-response hydrogel skeleton from chitosan or quaternary ammonium salt chitosan and a phenylboronic acid salt derivative, and then loading an mRNA vaccine and / or an immune checkpoint inhibitor for activating the immunity of dendritic cells (DC), the double-response hydrogel vaccine provided by the invention can significantly promote the activity of DC, can effectively activate antigen-specific T cells in vitro, and can significantly inhibit tumor recurrence.

The present invention discloses a pH / GSH program-responsive photothermal nanocomposite hydrogel co-drug-carrying system and a preparation method and application thereof, and belongs to the field of anti-tumor materials. The nanocomposite hydrogel co-drug-carrying system of the present invention is a pH-sensitive chitosan hydrogel co-carrying GSH stimulus-responsive drug-carrying nanoparticles encapsulated by hyaluronic acid and indocyanine green. The drug-carrying nanoparticles encapsulate tyrosine kinase inhibitors, and the chitosan hydrogel is obtained by cross-linking chitosan with polyethylene glycol-4-formylbenzoic acid. The nanocomposite hydrogel is easy to administer in situ, and the photothermal conversion of indocyanine green under near-infrared light irradiation is used to accurately thermally ablate the primary tumor; at the same time, the drug-carrying nanoparticles escape from the gel, respond to the release of the loaded tyrosine kinase inhibitor by GSH in the tumor cells, and inhibit tumor recurrence and metastasis. The nanocomposite hydrogel can achieve chemotherapy-photothermal synergistic therapy, enhance the therapeutic effect on tumors and reduce toxic side effects.

The invention discloses a PD1 gene engineering exosome preparation for cancer immunotherapy and a preparation method of the PD1 gene engineering exosome preparation. The invention provides a method for preparing an exosome for expressing PD1, and further provides any one of the following applications of the exosome as a drug carrier, delivery of drugs, preparation of tumor treatment products, preparation of postoperative tumor recurrence resistant products, preparation of postoperative tumor metastasis resistant products and the like. Genetically recombinantly engineered exosomes can be used to enhance the response of cancer immune checkpoint blocking therapies. The research also provides a new strategy with a prospect, and is used for enhancing the PD1 / PDL1 treatment effect, and postoperative tumor recurrence or metastasis is resisted by reconstructing the immunity of a patient, so that the overall prognosis is consolidated.

The present invention provides a method of determining the presence and / or location of a tumor, and / or the recurrence or metastasis of said tumor, comprising a photodynamic diagnosis based on a porphyrin dimer salt photosensitizer, and optionally a method of performing a photodynamic therapy based on a porphyrin dimer salt photosensitizer on said determined tumor, the invention also relates to application of the compound in diagnosis and treatment of tumors, especially tumors suitable for interventional diagnosis and treatment.

The application provides a radionuclide nanohydrogel microneedle and a preparation method and application thereof, and belongs to the field of nanobiomedicine. 32 P-labeled calcium phosphate, which is formed by a biomimetic reaction of Ag2S@Ca 32 P nanoparticles, and a base layer which is a base matrix and comprises hyaluronic acid 32 P nanohydrogel microneedle can release Ag2S nanoparticles in response to a weakly acidic tumor environment, and under the irradiation of near-infrared light, the photothermal conversion efficiency can effectively kill bacteria, effectively improve the tumor hypoxic environment, enhance the treatment effect of radionuclides, play an antibacterial and wound healing promoting role in melanoma defect repair, and maximize the inhibition of tumor growth and tumor recurrence.

The invention relates to the technical field of biological medicine, and provides a Chinese herbal medicine vesicle-LNP hybrid tumor mRNA vaccine and application thereof. The tumor mRNA vaccine disclosed by the invention is obtained by hybridizing Chinese herbal medicine nano-vesicles and lipid nano-particles loaded with tumor antigen mRNA. According to the invention, the characteristic of good biocompatibility of Chinese herbal medicines is utilized, so that the safety risk of the cationic lipid carrier is reduced. By combining the characteristics of Chinese herbal medicines, the nano-vesicles are extracted, so that the LNP is promoted to more effectively target antigen-presenting cells, the uptake level of the antigen-presenting cells is promoted, the phagocytosis of mRNA is enhanced, and the targeting and transcriptional expression level of mRNA can be enhanced. Finally, the Chinese herbal medicine nano vesicle-LNP hybrid tumor mRNA vaccine can strengthen the curative effects of inhibiting tumor progression, tumor recurrence and tumor metastasis after the tumor mRNA vaccine is inoculated, and a path is opened up for the combination of the tumor mRNA vaccine and richer immunotherapy means.

The invention relates to the technical field of biomedical engineering and drug delivery, and particularly discloses a novel targeted drug delivery system based on rose fruit extracellular vesicles, which comprises the following steps: preparing rose fruit source extracellular vesicles; preparing a medicine carrying vesicle; preparing targeted modified drug-loaded vesicles; according to the application disclosed by the invention, a stem related pathway is specifically down-regulated through the components of the rose fruits, and meanwhile, conventional tumor cells are killed by using adriamycin, so that a complementary treatment mechanism is formed, and the tumor recurrence risk is fundamentally reduced. The phenylboronic acid group of DSPE-PEG-PBA is used for specifically recognizing sialic acid over-expressed on the surface of a tumor cell, so that the enrichment of the medicine in tumor tissues is remarkably improved, and meanwhile, the distribution of normal tissues is reduced. By means of the natural biocompatibility and low immunogenicity of the RHNVs and in combination with the long circulation characteristic of a PEG chain, the delivery efficiency is guaranteed, the systemic toxicity is reduced to the maximum extent, and particularly the cardiotoxicity and myelosuppression of adriamycin are relieved.

A method and apparatus for the targeted delivery of chemotherapy to a surgical cavity, consisting of a triggered nanoparticle encapsulating a therapeutic agent and an energy delivery device that applied trigger energy to the surgical cavity. Following surgical removal of a cancerous tumor, the nanoparticle is administered, and the energy delivery device applies trigger energy to the surgical cavity and proximal tissue. The goal is the delivery of a therapeutic drug dose to cancerous and precancerous cells remaining after surgery, to prevent local tumor recurrence.

The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

A method and apparatus for the targeted delivery- of chemotherapy to a surgical cavity, including a triggered nanoparticle encapsulating a therapeutic agent and an energy delivery device that applied trigger energy- to the surgical cavity-. Following surgical removal of a cancerous tumor, the nanoparticle is administered, and the energy- delivery- device is configured to apply trigger energy to the surgical cavity and proximal tissue. Delivery of a therapeutic drug dose to cancerous and precancerous cells remaining after surgery may prevent local tumor recurrence.

The present disclosure relates to chimeric antigen receptor cells targeting ROBO1, in particular, enhanced CAR-T cells and CAR-NK cells targeting ROBO1, and preparation and application thereof. The cells can stably expressing CAR elements, while secreting extracellular domain molecules expressing PD-1 protein or mutants thereof, and thus may block PD-11PD-L1 molecular interaction. It has been found through animal experiments that the cells have very good anti-tumor effects, and the above-mentioned cells can significantly reduce tumor recurrence and improve the survival rate compared with the conventional ROBO1-targeted CAR modified cells.

The invention discloses a manganese urate material, a gel preparation and application thereof, and relates to the technical field of gel preparations. The manganese urate material provided by the invention can enhance anti-tumor immune response, and has good application prospects of adjuvants, vaccines and medicines. Besides, the invention also provides a gel preparation, the preparation is a multifunctional temperature-sensitive hydrogel preparation taking poloxamer as a matrix, and the preparation is combined with artesunate, adriamycin, uric acid and manganese to realize efficient treatment of various tumors such as breast cancer and inhibit postoperative recurrence of the tumors.

The invention relates to the technical field of application of glehnia littoralis, in particular to application of glehnia littoralis in preparation of drugs, and discloses new application of glehnia littoralis in preparation of drugs for preventing postoperative recurrence and metastasis of tumors, and the glehnia littoralis is applied to preparation of drugs for preventing postoperative recurrence and metastasis of tumors under the concentration of not causing cytotoxicity and toxic and side effects. Through multiple key steps of intervening tumor metastasis, including inhibition of adhesion of circulating tumor cells on vascular endothelial cells, inhibition of EMT transformation of the circulating tumor cells, inhibition of trans-endothelial migration of the circulating tumor cells and the like, the effect of preventing tumor metastasis or treating tumors is achieved, and meanwhile, the activity of immune cells is improved; the traditional Chinese medicine composition has the advantages of being capable of enhancing the killing ability of immune cells to circulating tumor cells, prolonging the lifetime, having extremely high safety, and solving the problems that the immune system and the rehabilitation ability are damaged in anti-cancer treatment by traditional medicines, the traditional cancer prevention and treatment strategy is limited and the like.

The application discloses a tumor recurrence risk prediction method and system based on electronic medical record data, relates to the field of electronic medical record data processing and analysis, and can realize individualized recurrence risk assessment based on multidimensional characteristics, significantly reduces subjective judgment errors, and establishes a recurrence risk mapping model through structured processing of historical electronic medical record data; a risk grade stratification mechanism can automatically distinguish patients who need emergency intervention from patients who need routine monitoring, avoids excessive medical treatment or delayed treatment, and is especially suitable for chronic diseases such as tumors that need long-term management; through periodic marker measurement and risk grade feedback, a closed-loop management of 'assessment-intervention-reassessment' is formed, meeting the needs of continuous optimization of clinical diagnosis and treatment; in addition, through preprocessing, multidimensional characteristics after preprocessing can be directly called in the subsequent process, and repeated data cleaning work is avoided.

The invention provides a tumor radiotherapy rehabilitation abnormity early warning method and system, and relates to the technical field of medical data analysis, and the method comprises the steps: obtaining a first tumor CT image and first image feature information thereof, first focus region detection information and first focus feature information after the first reexamination after tumor radiotherapy treatment; and after the kth review, obtaining a second tumor CT image and second image feature information thereof, and obtaining second focus area detection information and second focus feature information in combination with the first focus feature information so as to determine abnormal early warning information. According to the method and the device, the tumor CT image obtained after each review can be processed by using the anomaly recognition model, and during processing, the tumor CT image obtained during the previous review is combined for comprehensive analysis, and the condition and change of a focus can be analyzed, so that the comprehensiveness and the accuracy of analysis are improved, the distinguishing accuracy of pseudomorphism and tumor recurrence is improved, and the success rate of tumor review is improved. And the early warning accuracy is improved.

The invention discloses an iron-doped molybdenum oxide synergistically enhanced polycaprolactone breast patch and a preparation method thereof.The preparation method comprises the following steps that ferric chloride hexahydrate serves as an iron source, ammonium molybdate tetrahydrate serves as a molybdenum source, and Fe-MoOv nano-enzyme rich in oxygen vacancies is prepared through a simple one-step solvothermal method; then, the Fe-MoOv nano enzyme and polycaprolactone (PCL) powder are dispersed in ethyl alcohol, and PCL / Fe-MoOv composite powder is obtained through ultrasonic mixing, centrifugal drying and grinding; finally, the composite powder is prepared into the PCL / Fe-MoOv breast patch through a selective laser sintering technology, the obtained PCL / Fe-MoOv breast patch aims at providing necessary mechanical support for a prosthesis implanted in the breast reconstruction process after a breast cancer operation and effectively inhibiting tumor recurrence, and the PCL / Fe-MoOv breast patch has the excellent photo-thermal performance and can be used for preparing the breast patch. The PCL / Fe-MoOv breast patch disclosed by the invention realizes combined treatment of a photothermal therapy and a chemodynamic therapy, has a remarkable anti-tumor effect, and has a wide application prospect in the field of breast cancer treatment.

This invention relates to the field of biotechnology, specifically to a TruC-T cell that secretes and expresses IL-7 and PF4 to enhance anti-tumor activity and targets uPAR, and its application. Interleukin-7 (IL-7) can effectively promote the development, survival, and proliferation of T cells, while platelet factor 4 (PF4 / CXCL4) can regulate the immune response and chemotactically attract leukocytes to specific sites; the synergistic effect of the two can enhance the anti-tumor function and persistence of T cells. Meanwhile, urokinase-type plasminogen activator receptor (uPAR) is highly expressed in various solid tumors and hematological malignancies, making it an ideal target for tumor therapy; TruC-T cells targeting uPAR can precisely act on tumor tissue, and combined with the immune-enhancing effects of IL-7 and PF4, can significantly improve the efficacy of anti-tumor immune responses, prolong the duration of therapeutic effects, and reduce tumor recurrence.

The application discloses a novel AIE photosensitizer and a preparation method and application thereof. The AIE photosensitizer of the application comprises TDQ shown in the following structural formula, has superior photo-thermal conversion performance and photodynamic performance, and can be used for preparing a tumor diagnosis reagent or a tumor treatment drug. The co-loading liposome of TDQ and a senescence-inducing molecule (Ali) can be used as a multi-modal light diagnosis and treatment agent to realize efficient delivery of drugs to tumor tissues, and the photo-thermal therapy and the photodynamic therapy based on TDQ not only induce cell apoptosis through oxidative stress and mitochondrial dysfunction, but also trigger cancer cell senescence and promote the secretion of SASPs, so that the anti-tumor immunity is significantly enhanced, and finally the growth of primary tumors, tumor recurrence and re-metastasis are inhibited. The material of the application has simple preparation process, low cost, and is suitable for scale production and clinical medical use.

The invention belongs to the technical field of biological medicine, and particularly relates to application of an anti-HIV drug in inhibition of non-small cell lung cancer drug resistance. The invention finds that the combined use of the anti-HIV drug and EGFR-TKI can effectively and specifically target the MRD drug-resistant cells, inhibit the formation of the MRD drug-resistant cells, significantly improve the curative effect of EGFR-TKI and delay tumor recurrence.

The invention discloses a preparation method and application of nano particles for treating oral squamous cell carcinoma, the multifunctional nano particles take dendritic macroporous mesoporous silica as a template, titanium dioxide continues to grow on the surface of the template, and then the obtained mesoporous titanium dioxide is subjected to quaternary ammonium functionalization to obtain the nano particles for treating oral squamous cell carcinoma. And finally, carrying porphyromonas gingivalis cell walls with multiple functions through electrostatic interaction. The nano particles have sonodynamic and chemical dynamic therapy performance, hydrogen peroxide can be catalyzed to generate oxygen, the oxygen and glutathione are subjected to an oxidation-reduction reaction, and carried porphyromonas gingivalis cell walls can activate anti-tumor immune response. The nanoparticles can be used for treating oral squamous cell carcinoma in combination with sonodynamic, chemical dynamic and bacterial immunity under ultrasonic excitation, and recurrence and metastasis of tumors are effectively inhibited through combination of multiple strategies. The method is reasonable in design and simple to operate, can improve the treatment effect of oral squamous cell carcinoma, and has important clinical significance.

The present invention relates to an oncolytic adenovirus capable of co-expressing interleukin-12 and a C-met-inhibiting oligonucleotide; and an antitumor immune-boosting composition and anticancer composition comprising the oncolytic adenovirus. The present invention has first identified an adenovirus system having simultaneous effects of IL-12 expression and C-met inhibition in cancer gene treatment. The adenovirus system of the present invention is capable of inhibiting C-met while expressing interleukin-12, thereby restoring immune functions in a tumor environment to enhance anticancer effects such as the inhibition of tumor recurrence and tumor growth and to inhibit tumor migration. Accordingly, the adenovirus system of the present invention can be effectively used in the treatment of cancer.

The application discloses a bispecific chimeric antigen receptor targeting HER2 and HLA-G and application thereof, and belongs to the tumor immunotherapy field.The chimeric antigen receptor comprises an extracellular domain, a hinge domain, a transmembrane domain and at least one intracellular domain, and the extracellular domain comprises an anti-HER2 single-chain antibody and an anti-HLA-G single-chain antibody.The bispecific chimeric antigen receptor of the application can effectively improve the killing signal of immune cells, and can effectively avoid the inhibition of the immunosuppressive signal on the function of immune cells, thereby delaying the recurrence of tumors, and has very important clinical application value.